Lilly box for the US swim trials with Bella!

Support my Breakthrough T1D Walk representing Boston team Lilly! www2.breakthrought1d.org/site/TR?fr_id=…

Join us for the exciting program at Aegean's First International Conference on Obesity - Biological Drivers and Therapeutic Approaches - Abstract Submission now open! aegeanconferences.org/src/App/confer…

Join us for the 2025 Obesity and Adipose Tissue #Keytstone Meeting in Banff. We are looking forward to stimulating presentations from leading researchers across the world. Consider submitting abstract to share your most exciting science. youtu.be/-HREW7CMhbg?si… via YouTube

I’ve been getting a lot of requests for advice on moving from academia to industry. Here are my thoughts and the resources that helped guide my job search strategy:

Reminder: Register and submit your abstract by Feb. 1, 2025 to the First Int'l Conference on #Obesity - #BiologicalDrivers and #Therapeutic Approaches aegeanconferences.org/src/App/confer… May 20-25 in #Crete, #Greece KALIMERA KRITI Funds available for students/trainees! Apply!

It'll be a blast!

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis

Proud dad moment!

New DiabetesBio episode is out with fantastic authors Jenny Bruin Lahari Basu and a special segment celebrating #DavidWasserman YT: shorturl.at/ndZRY 🎧: shorturl.at/brjIv 🍎: shorturl.at/L6qTb 👇A symposium honoring Dave is coming this June, don’t miss it👇

Only a few weeks away from exploring the various exciting aspects of obesity biology and therapeutics in lovely Crete! Come and join us to review the latest with an amazing speaker lineup! aegeanconferences.org/src/App/confer…

Incredibly proud of this work. We detail the evolution of liver-secreted and plasma proteins with MASLD progression, providing a rich resource defining human hepatokines and a predictive model that stratifies MASH. William De Nardo UniMelb MDHS cell.com/cell-reports-m…

While the latest GLP-1 medicines are “new” exenatide was approved April 28 2005. Congratulations to John Eng, Amylin Pharma and the hundreds of visionary persistent investigators who gave birth to the class of GLP-1 medicines for type 2 #diabetes youtube.com/watch?v=WiHHqs…

See new job opportunity in our lab. •Collaborate with world-leading industry partner •Join a dynamic team advancing metabolic disease research and shaping the future of obesity treatments unimelb.wd105.myworkdayjobs.com/UoM_External_C…

About a month to go to submit abstracts for the premier Obesity science meeting at Keystone, CO. Amazing speaker lineup, come along to connect and learn. keystonesymposia.org/conferences/co…

I'm walking for type 1 diabetes again this year - an amazing event to support a worthwhile cause. Any help greatly appreciate... Participant Center - BreakthroughT1D Walk www2.breakthrought1d.org/site/TR?fr_id=…

Proud to feature world-class leaders driving discovery and innovation: Prof Lora Heisler Jim Trevaskis Matthias Tschöp Daniel P Kelly Rong Tian, MD PhD Join them Jan 26–29, 2026 in Keystone, CO! #KSObesity26 #KSCardioMetab26

From the lizard venom and John Eng, in licensing to clinical development and approval April 28 2005. The remarkable story of Amylin Pharma and exenatide nature.com/articles/s4225…

A small passion project came out today! Terrific reconnecting with former colleagues at Amylin Pharmaceuticals to write this on the 20th anniversary of the first approved GLP-1R agonist. rdcu.be/eH7OA